Merck KGaA Reports the Acquisition of Mirus Bio, Strengthening Upstream Portfolio
Shots:
- Merck KGaA has entered into a definitive agreement to acquire Mirus Bio (part of Gamma Biosciences) for an aggregate of $600M to strengthen its upstream portfolio. The transaction is expected to conclude in Q3’24
- The acquisition adds Mirus Bio’s transfection reagents namely, TransIT-VirusGEN, to Merck’s portfolio that are essential for the production of viral vector-based gene therapies
- Furthermore, the acquisition enables Merck advancing its aim to offer wide-ranging solutions for viral vector manufacturing to focus on gene therapies and novel modalities
Ref: Merck KGaA | Image: Merck KGaA
Related News:- Caris Life Sciences Collaborates with Merck KGaA to Discover and Develop Antibody Drug Conjugate for Cancer Treatment
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
